nach oben

Arthritis Research & Therapy

Erschienen in:

01.04.2010 | Review

Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise

verfasst von: Salahuddin Ahmed

Erschienen in: Arthritis Research & Therapy | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Green tea's active ingredient, epigallocatechin 3-gallate (EGCG), has gained significant attention among scientists and has been one of the leading plant-derived molecules studied for its potential health benefits. In the present review I summarize the findings from some of the most significant preclinical studies with EGCG in arthritic diseases. The review also addresses the limitations of the dose, pharmacokinetics, and bioavailability of EGCG in experimental animals and findings related to the EGCG-drug interaction. Although these findings provide scientific evidence of the anti-rheumatic activity of EGCG, further preclinical studies are warranted before phase clinical trials could be initiated with confidence for patients with joint diseases.

Pope RM: Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol. 2002, 2: 527-535. 10.1038/nri846.CrossRefPubMed

Feldmann M, Maini SR: Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev. 2008, 223: 7-19. 10.1111/j.1600-065X.2008.00626.x.CrossRefPubMed

Samuels J, Krasnokutsky S, Abramson SB: Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis. 2008, 66: 244-250.PubMed

Malemud CJ, Islam N, Haqqi TM: Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies. Cells Tissues Organs. 2003, 174: 34-48. 10.1159/000070573.CrossRefPubMed

Siddiqui MA: The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence. Curr Opin Rheumatol. 2007, 19: 308-313. 10.1097/01.bor.0000265447.48722.04.CrossRefPubMed

van Vollenhoven RF: Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol. 2009, 5: 531-541. 10.1038/nrrheum.2009.182.CrossRefPubMed

Fox BA, Stephens MM: Glucosamine/chondroitin/primorine combination therapy for osteoarthritis. Drugs Today (Barc). 2009, 45: 21-31. 10.1358/dot.2009.45.1.1314053.CrossRef

Felson DT: Developments in the clinical understanding of osteoarthritis. Arthritis Res Ther. 2009, 11: 203-10.1186/ar2531.PubMedCentralCrossRefPubMed

Callahan LF, Wiley-Exley EK, Mielenz TJ, Brady TJ, Xiao C, Currey SS, Sleath BL, Sloane PD, DeVellis RF, Sniezek J: Use of complementary and alternative medicine among patients with arthritis. Prev Chronic Dis. 2009, 6: A44-PubMedCentralPubMed

10.

Kikuchi M, Matsuura K, Matsumoto Y, Inagaki T, Ueda R: Bibliographical investigation of complementary alternative medicines for osteoarthritis and rheumatoid arthritis. Geriatr Gerontol Int. 2009, 9: 29-40. 10.1111/j.1447-0594.2008.00503.x.CrossRefPubMed

11.

Marcus DM: Therapy: herbals and supplements for rheumatic diseases. Nat Rev Rheumatol. 2009, 5: 299-300. 10.1038/nrrheum.2009.89.CrossRefPubMed

12.

Manning J, Roberts JC: Analysis of catechin content of commercial green tea products. J Herb Pharmacother. 2003, 3: 19-32. 10.1300/J157v03n03_03.CrossRefPubMed

13.

Doss MX, Potta SP, Hescheler J, Sachinidis A: Trapping of growth factors by catechins: a possible therapeutical target for prevention of proliferative diseases. J Nutr Biochem. 2005, 16: 259-266. 10.1016/j.jnutbio.2004.11.003.CrossRefPubMed

14.

Cooper R, Morre DJ, Morre DM: Medicinal benefits of green tea: part I. Review of noncancer health benefits. J Altern Complement Med. 2005, 11: 521-528. 10.1089/acm.2005.11.521.CrossRefPubMed

15.

Ahmed S, Rahman A, Hasnain A, Lalonde M, Goldberg VM, Haqqi TM: Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med. 2002, 33: 1097-1105. 10.1016/S0891-5849(02)01004-3.CrossRefPubMed

16.

Singh R, Ahmed S, Islam N, Goldberg VM, Haqqi TM: Epigallocatechin-3-gallate inhibits interleukin-1β-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor κB activation by degradation of the inhibitor of nuclear factor κB. Arthritis Rheum. 2002, 46: 2079-2086. 10.1002/art.10443.CrossRefPubMed

17.

Singh R, Ahmed S, Malemud CJ, Goldberg VM, Haqqi TM: Epigallocatechin-3-gallate selectively inhibits interleukin-1beta-induced activation of mitogen activated protein kinase subgroup c-Jun N-terminal kinase in human osteoarthritis chondrocytes. J Orthop Res. 2003, 21: 102-109. 10.1016/S0736-0266(02)00089-X.CrossRefPubMed

18.

Brinckerhoff CE, Matrisian LM: Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 2002, 3: 207-214. 10.1038/nrm763.CrossRefPubMed

19.

Dahlberg L, Billinghurst RC, Manner P, Nelson F, Webb G, Ionescu M, Reiner A, Tanzer M, Zukor D, Chen J, van Wart HE, Poole AR: Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum. 2000, 43: 673-682. 10.1002/1529-0131(200003)43:3<673::AID-ANR25>3.0.CO;2-8.CrossRefPubMed

20.

Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF, Hambor JE: Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest. 1996, 97: 761-768. 10.1172/JCI118475.PubMedCentralCrossRefPubMed

21.

Ahmed S, Wang N, Lalonde M, Goldberg VM, Haqqi TM: Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. J Pharmacol Exp Ther. 2004, 308: 767-773. 10.1124/jpet.103.059220.CrossRefPubMed

22.

Adcocks C, Collin P, Buttle DJ: Catechins from green tea (Camellia sinensis) inhibit bovine and human cartilage proteoglycan and type II collagen degradation in vitro. J Nutr. 2002, 132: 341-346.PubMed

23.

Vankemmelbeke MN, Jones GC, Fowles C, Ilic MZ, Handley CJ, Day AJ, Knight CG, Mort JS, Buttle DJ: Selective inhibition of ADAMTS-1, -4 and -5 by catechin gallate esters. Eur J Biochem. 2003, 270: 2394-2403. 10.1046/j.1432-1033.2003.03607.x.CrossRefPubMed

24.

Andriamanalijaona R, Kypriotou M, Bauge C, Renard E, Legendre F, Raoudi M, Boumediene K, Gatto H, Monginoux P, Pujol JP: Comparative effects of 2 antioxidants, selenomethionine and epigallocatechin-gallate, on catabolic and anabolic gene expression of articular chondrocytes. J Rheumatol. 2005, 32: 1958-1967.PubMed

25.

Rasheed Z, Anbazhagan AN, Akhtar N, Ramamurthy S, Voss FR, Haqqi TM: Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes. Arthritis Res Ther. 2009, 11: R71-10.1186/ar2700.PubMedCentralCrossRefPubMed

26.

Goo HC, Hwang YS, Choi YR, Cho HN, Suh H: Development of collagenase-resistant collagen and its interaction with adult human dermal fibroblasts. Biomaterials. 2003, 24: 5099-5113. 10.1016/S0142-9612(03)00431-9.CrossRefPubMed

27.

Bae JY, Matsumura K, Wakitani S, Kawaguchi A, Tsutsumi S, Hyon SH: Beneficial storage effects of epigallocatechin-3-o-gallate on the articular cartilage of rabbit osteochondral allografts. Cell Transplant. 2009, 18: 505-512. 10.3727/096368909788809776.CrossRefPubMed

28.

Han DW, Bae JY, Matsumura K, Wakitani S, Nawata M, Hyon SH: Non-frozen preservation of articular cartilage by epigallocatechin-3-gallate reversibly regulating cell cycle and NF-κB expression. Tissue Eng Part A. 2009,

29.

Leibbrandt A, Penninger JM: RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 2008, 1143: 123-150. 10.1196/annals.1443.016.CrossRefPubMed

30.

Hafeez BB, Ahmed S, Wang N, Gupta S, Zhang A, Haqqi TM: Green tea polyphenols-induced apoptosis in human osteosarcoma SAOS-2 cells involves a caspase-dependent mechanism with downregulation of nuclear factor-κB. Toxicol Appl Pharmacol. 2006, 216: 11-19. 10.1016/j.taap.2006.03.013.CrossRefPubMed

31.

Lin SK, Chang HH, Chen YJ, Wang CC, Galson DL, Hong CY, Kok SH: Epigallocatechin-3-gallate diminishes CCL2 expression in human osteoblastic cells via up-regulation of phosphatidylinositol 3-Kinase/Akt/Raf-1 interaction: a potential therapeutic benefit for arthritis. Arthritis Rheum. 2008, 58: 3145-3156. 10.1002/art.23937.CrossRefPubMed

32.

Kishimoto T: IL-6: from laboratory to bedside. Clin Rev Allergy Immunol. 2005, 28: 177-186. 10.1385/CRIAI:28:3:177.CrossRefPubMed

33.

Nishimoto N: Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol. 2006, 18: 277-281. 10.1097/01.bor.0000218949.19860.d1.CrossRefPubMed

34.

Tokuda H, Takai S, Hanai Y, Matsushima-Nishiwaki R, Hosoi T, Harada A, Ohta T, Kozawa O: (-)-Epigallocatechin gallate suppresses endothelin-1-induced interleukin-6 synthesis in osteoblasts: inhibition of p44/p42 MAP kinase activation. FEBS Lett. 2007, 581: 1311-1316. 10.1016/j.febslet.2007.02.052.CrossRefPubMed

35.

Kamon M, Zhao R, Sakamoto K: Green tea polyphenol (-)-epigallocatechin gallate suppressed the differentiation of murine osteoblast MC3T3-E1 cell. Cell Biol Int. 2009, 34: 109-116.PubMed

36.

Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH: Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the NF-κB signal. Mol Pharmacol. 2010, 77: 17-25. 10.1124/mol.109.057877.CrossRefPubMed

37.

Ahmed S, Pakozdi A, Koch AE: Regulation of interleukin-1β-induced chemokine production and matrix metalloproteinase 2 activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2006, 54: 2393-2401. 10.1002/art.22023.CrossRefPubMed

38.

Marotte H, Ruth JH, Campbell PL, Koch AE, Ahmed S: Green tea extract inhibits chemokine production, but up-regulates chemokine receptor expression, in rheumatoid arthritis synovial fibroblasts and rat adjuvant-induced arthritis. Rheumatology (Oxford). 2010, 49: 467-479. 10.1093/rheumatology/kep397.CrossRef

39.

Corps AN, Curry VA, Buttle DJ, Hazleman BL, Riley GP: Inhibition of interleukin-1β-stimulated collagenase and stromelysin expression in human tendon fibroblasts by epigallocatechin gallate ester. Matrix Biol. 2004, 23: 163-169. 10.1016/j.matbio.2004.05.001.CrossRefPubMed

40.

Cronstein BN: Interleukin-6 - a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007, 65 (Suppl 1): S11-S15.PubMed

41.

Ahmed S, Marotte H, Kwan K, Ruth JH, Campbell PL, Rabquer BJ, Pakozdi A, Koch AE: Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proc Natl Acad Sci USA. 2008, 105: 14692-14697. 10.1073/pnas.0802675105.PubMedCentralCrossRefPubMed

42.

Yun HJ, Yoo WH, Han MK, Lee YR, Kim JS, Lee SI: Epigallocatechin-3-gallate suppresses TNF-α-induced production of MMP-1 and -3 in rheumatoid arthritis synovial fibroblasts. Rheumatol Int. 2008, 29: 23-29. 10.1007/s00296-008-0597-5.CrossRefPubMed

43.

Zhang HG, Huang N, Liu D, Bilbao L, Zhang X, Yang P, Zhou T, Curiel DT, Mountz JD: Gene therapy that inhibits nuclear translocation of nuclear factor κB results in tumor necrosis factor alpha-induced apoptosis of human synovial fibroblasts. Arthritis Rheum. 2000, 43: 1094-1105. 10.1002/1529-0131(200005)43:5<1094::AID-ANR20>3.0.CO;2-V.CrossRefPubMed

44.

Zhang HG, Wang Y, Xie JF, Liang X, Liu D, Yang P, Hsu HC, Ray RB, Mountz JD: Regulation of tumor necrosis factor alpha-mediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt. Arthritis Rheum. 2001, 44: 1555-1567. 10.1002/1529-0131(200107)44:7<1555::AID-ART279>3.0.CO;2-M.CrossRefPubMed

45.

Liu H, Eksarko P, Temkin V, Haines GK, Perlman H, Koch AE, Thimmapaya B, Pope RM: Mcl-1 is essential for the survival of synovial fibroblasts in rheumatoid arthritis. J Immunol. 2005, 175: 8337-8345.CrossRefPubMed

46.

Ahmed S, Silverman MD, Marotte H, Kwan K, Matuszczak N, Koch AE: Down-regulation of myeloid cell leukemia 1 by epigallocatechin-3-gallate sensitizes rheumatoid arthritis synovial fibroblasts to tumor necrosis factor alpha-induced apoptosis. Arthritis Rheum. 2009, 60: 1282-1293. 10.1002/art.24488.PubMedCentralCrossRefPubMed

47.

Haqqi TM, Anthony DD, Gupta S, Ahmad N, Lee MS, Kumar GK, Mukhtar H: Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci USA. 1999, 96: 4524-4529. 10.1073/pnas.96.8.4524.PubMedCentralCrossRefPubMed

48.

Lin RW, Chen CH, Wang YH, Ho ML, Hung SH, Chen IS, Wang GJ: (-)-Epigallocatechin gallate inhibition of osteoclastic differentiation via NF-κB. Biochem Biophys Res Commun. 2009, 379: 1033-1037. 10.1016/j.bbrc.2009.01.007.CrossRefPubMed

49.

Morinobu A, Biao W, Tanaka S, Horiuchi M, Jun L, Tsuji G, Sakai Y, Kurosaka M, Kumagai S: (-)-Epigallocatechin-3-gallate suppresses osteoclast differentiation and ameliorates experimental arthritis in mice. Arthritis Rheum. 2008, 58: 2012-2018. 10.1002/art.23594.CrossRefPubMed

50.

Natsume H, Adachi S, Takai S, Tokuda H, Matsushima-Nishiwaki R, Minamitani C, Yamauchi J, Kato K, Mizutani J, Kozawa O, Otsuka T: (-)-Epigallocatechin gallate attenuates the induction of HSP27 stimulated by sphingosine 1-phosphate via suppression of phosphatidylinositol 3-kinase/Akt pathway in osteoblasts. Int J Mol Med. 2009, 24: 197-203.PubMed

51.

Takai S, Matsushima-Nishiwaki R, Adachi S, Natsume H, Minamitani C, Mizutani J, Otsuka T, Tokuda H, Kozawa O: (-)-Epigallocatechin gallate reduces platelet-derived growth factor-BB-stimulated interleukin-6 synthesis in osteoblasts: suppression of SAPK/JNK. Mediators Inflamm. 2008, 2008: 291808-10.1155/2008/291808.PubMedCentralCrossRefPubMed

52.

Kim HR, Rajaiah R, Wu QL, Satpute SR, Tan MT, Simon JE, Berman BM, Moudgil KD: Green tea protects rats against autoimmune arthritis by modulating disease-related immune events. J Nutr. 2008, 138: 2111-2116. 10.3945/jn.108.089912.PubMedCentralCrossRefPubMed

53.

Elmets CA, Singh D, Tubesing K, Matsui M, Katiyar S, Mukhtar H: Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. J Am Acad Dermatol. 2001, 44: 425-432. 10.1067/mjd.2001.112919.CrossRefPubMed

54.

Shanafelt TD, Lee YK, Call TG, Nowakowski GS, Dingli D, Zent CS, Kay NE: Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res. 2006, 30: 707-712. 10.1016/j.leukres.2005.10.020.CrossRefPubMed

55.

McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA: Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res. 2009, 2: 673-682. 10.1158/1940-6207.CAPR-08-0167.CrossRef

56.

Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE: Phase I trial of daily oral polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol. 2009, 27: 3808-3814. 10.1200/JCO.2008.21.1284.PubMedCentralCrossRefPubMed

57.

Brown AL, Lane J, Coverly J, Stocks J, Jackson S, Stephen A, Bluck L, Coward A, Hendrickx H: Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial. Br J Nutr. 2009, 101: 886-894. 10.1017/S0007114508047727.PubMedCentralCrossRefPubMed

58.

Maki KC, Reeves MS, Farmer M, Yasunaga K, Matsuo N, Katsuragi Y, Komikado M, Tokimitsu I, Wilder D, Jones F, Blumberg JB, Cartwright Y: Green tea catechin consumption enhances exercise-induced abdominal fat loss in overweight and obese adults. J Nutr. 2009, 139: 264-270.CrossRefPubMed

59.

Hsu CH, Tsai TH, Kao YH, Hwang KC, Tseng TY, Chou P: Effect of green tea extract on obese women: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2008, 27: 363-370. 10.1016/j.clnu.2008.03.007.CrossRefPubMed

60.

Isbrucker RA, Edwards JA, Wolz E, Davidovich A, Bausch J: Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and short-term toxicity studies. Food Chem Toxicol. 2006, 44: 636-650. 10.1016/j.fct.2005.11.003.CrossRefPubMed

61.

Chen L, Lee MJ, Li H, Yang CS: Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab Dispos. 1997, 25: 1045-1050.PubMed

62.

Kim S, Lee MJ, Hong J, Li C, Smith TJ, Yang GY, Seril DN, Yang CS: Plasma and tissue levels of tea catechins in rats and mice during chronic consumption of green tea polyphenols. Nutr Cancer. 2000, 37: 41-48. 10.1207/S15327914NC3701_5.CrossRefPubMed

63.

Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, Hara Y, Alberts DS: Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res. 2003, 9: 3312-3319.PubMed

64.

Chow HH, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J, Chew WM, Celaya CA, Rodney SR, Hara Y, Alberts DS: Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals. Clin Cancer Res. 2005, 11: 4627-4633. 10.1158/1078-0432.CCR-04-2549.CrossRefPubMed

65.

Manach C, Williamson G, Morand C, Scalbert A, Remesy C: Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr. 2005, 81 (1 Suppl): 230S-242S.PubMed

66.

Williamson G, Manach C: Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr. 2005, 81 (1 Suppl): 243S-255S.PubMed

67.

Umegaki K, Sugisawa A, Yamada K, Higuchi M: Analytical method of measuring tea catechins in human plasma by solid-phase extraction and HPLC with electrochemical detection. J Nutr Sci Vitaminol. 2001, 47: 402-408.CrossRefPubMed

68.

Yang CS, Chen L, Lee MJ, Balentine D, Kuo MC, Schantz SP: Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev. 1998, 7: 351-354.PubMed

69.

Adhami VM, Malik A, Zaman N, Sarfaraz S, Siddiqui IA, Syed DN, Afaq F, Pasha FS, Saleem M, Mukhtar H: Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res. 2007, 13: 1611-1619. 10.1158/1078-0432.CCR-06-2269.CrossRefPubMed

70.

Siddiqui IA, Malik A, Adhami VM, Asim M, Hafeez BB, Sarfaraz S, Mukhtar H: Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene. 2008, 27: 2055-2063. 10.1038/sj.onc.1210840.CrossRefPubMed

71.

Jungel A, Baresova V, Ospelt C, Simmen BR, Michel BA, Gay RE, Gay S, Seemayer CA, Neidhart M: Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis. Ann Rheum Dis. 2006, 65: 910-912. 10.1136/ard.2005.044065.PubMedCentralCrossRefPubMed

72.

Kim MH: Protein phosphatase 1 activation and alternative splicing of Bcl-X and Mcl-1 by EGCG + ibuprofen. J Cell Biochem. 2008, 104: 1491-1499. 10.1002/jcb.21725.CrossRefPubMed

73.

Sakla MS, Lorson CL: Induction of full-length survival motor neuron by polyphenol botanical compounds. Hum Genet. 2008, 122: 635-643. 10.1007/s00439-007-0441-0.CrossRefPubMed

74.

Golden EB, Lam PY, Kardosh A, Gaffney KJ, Cadenas E, Louie SG, Petasis NA, Chen TC, Schonthal AH: Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood. 2009, 113: 5927-5937. 10.1182/blood-2008-07-171389.CrossRefPubMed

75.

Yang H, Zonder JA, Dou QP: Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin Investig Drugs. 2009, 18: 957-971. 10.1517/13543780903002074.PubMedCentralCrossRefPubMed

76.

Zaveri NT: Synthesis of a 3,4,5-trimethoxybenzoyl ester analogue of epigallocatechin-3-gallate (EGCG): a potential route to the natural product green tea catechin, EGCG. Org Lett. 2001, 3: 843-846. 10.1021/ol007000o.CrossRefPubMed

77.

Waleh NS, Chao WR, Bensari A, Zaveri NT: Novel D-ring analog of epigallocatechin-3-gallate inhibits tumor growth and VEGF expression in breast carcinoma cells. Anticancer Res. 2005, 25: 397-402.PubMed

78.

Barras A, Mezzetti A, Richard A, Lazzaroni S, Roux S, Melnyk P, Betbeder D, Monfilliette-Dupont N: Formulation and characterization of polyphenolloaded lipid nanocapsules. Int J Pharm. 2009, 379: 270-277. 10.1016/j.ijpharm.2009.05.054.CrossRefPubMed

79.

Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI, Ahmad N, Cui H, Mousa SA, Mukhtar H: Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 2009, 69: 1712-1716. 10.1158/0008-5472.CAN-08-3978.PubMedCentralCrossRefPubMed

80.

Smith A, Giunta B, Bickford PC, Fountain M, Tan J, Shytle RD: Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. Int J Pharm. 389: 207-212. 10.1016/j.ijpharm.2010.01.012.

81.

Boschmann M, Thielecke F: The effects of epigallocatechin-3-gallate on thermogenesis and fat oxidation in obese men: a pilot study. J Am Coll Nutr. 2007, 26: 389S-395S.CrossRefPubMed

82.

Carlson JR, Bauer BA, Vincent A, Limburg PJ, Wilson T: Reading the tea leaves: anticarcinogenic properties of (-)-epigallocatechin-3-gallate. Mayo Clin Proc. 2007, 82: 725-732. 10.4065/82.6.725.CrossRefPubMed

Titel: Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise
verfasst von: Salahuddin Ahmed
Publikationsdatum: 01.04.2010
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 2/2010
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar2982

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin

Attenuation of fibrosis in vitro and in vivo with SPARC siRNA

Which patients with rheumatoid arthritis are still working?

Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints

Vasculogenesis in rheumatoid arthritis

B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin